Trendlines Group, which is an investment group focused on agrifood and medtech innovation, has a 11.2% stake, post series A funding round, in the portfolio company IBI Ag.

 

IBI Ag was founded and incubated by Trendlines, and its proprietary platform adapts single-domain antibody technology from human therapeutics to agriculture, enabling the development of precise, environmentally responsible bioinsecticides.

 

This approach has the potential to transform pest management by protecting high value crops while preserving beneficial insect species.

 

The $10 million financing round is led by Corteva, through its Corteva Catalyst platform. The round included participation from The Trendlines Group, Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures, and a grant from the Israel Innovation Authority.